Related references
Note: Only part of the references are listed.Influence of skin color in the development of erlotinib-induced rash: A report from the SERIES clinic
S. E. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The kinase inhibitor imatinib - An immunosuppressive drug?
D. Wolf et al.
CURRENT CANCER DRUG TARGETS (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Hand-foot and stump syndrome to sorafenib
Susan E. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab in the management of solid tumors
Roy L. Panares et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma
Kun-Ying Tsai et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
Ferry A. L. M. Eskens et al.
EUROPEAN JOURNAL OF CANCER (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
Alessandro Morabito et al.
ONCOLOGIST (2006)
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
D Strumberg et al.
EUROPEAN JOURNAL OF CANCER (2006)
The frequency and significance of thiopurine S-methyltransferase gene polymorphisms in azathioprine-treated renal transplant recipients
F. J. . Moloney et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction
Isrnail Guz Kara et al.
BREAST (2006)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
Release of doxorubicin in sweat:: first step to induce the palmarplantar erythrodysesthesia syndrome?
U Jacobi et al.
ANNALS OF ONCOLOGY (2005)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies
RD Drake et al.
GYNECOLOGIC ONCOLOGY (2004)
Current Canadian experience with capecitabine - Partnering with patients to optimize therapy
BM Gerbrecht
CANCER NURSING (2003)
BAY 43-9006: Preclinical data
S Wilhelm et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors
C Eng et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
